Abogen Biosciences

Abogen Biosciences (Suzhou Abogen Biosciences Co., Ltd.) is a privately held Chinese biotechnology company focused on the discovery, development and manufacturing of messenger RNA (mRNA) therapeutics and vaccines. Founded in 2019 and headquartered in Suzhou, Jiangsu Province, the company was established to build an integrated mRNA platform covering sequence design, delivery technology and large-scale production. Its founding team includes Ying Bo, a scientist with experience in nucleic-acid drug delivery, who has served as the company's chairman and chief executive. Abogen's core technology is its proprietary lipid nanoparticle (LNP) delivery system, which is designed to protect and transport mRNA into cells. The company has applied this platform across infectious-disease vaccines and therapeutic areas. Its most widely recognized program is ARCoV, a COVID-19 mRNA vaccine candidate developed in collaboration with the Academy of Military Medical Sciences and Walvax Biotechnology. ARCoV was among the first homegrown Chinese mRNA COVID-19 vaccine candidates to enter clinical trials and was designed to be stable at refrigerator temperatures, a practical advantage for distribution in regions with limited cold-chain infrastructure. Beyond COVID-19, Abogen has pursued a pipeline that includes mRNA vaccine candidates for other infectious diseases and mRNA-based therapeutics in areas such as oncology and rare diseases. The company has attracted significant venture and strategic investment from Chinese and international investors, reflecting broad interest in mRNA as a platform technology. It operates research and manufacturing facilities in China and has emphasized building domestic mRNA production capacity. As a private company, Abogen does not disclose detailed financial results publicly. Its brand identity is closely tied to the mRNA platform and to the ambition of establishing China-based mRNA drug development and manufacturing capability. The company remains active in research and development and continues to be associated with the advancement of mRNA technology in China.

Abogen Biosciences was founded in 2019 in Suzhou, Jiangsu Province, China, with the goal of building a domestic mRNA drug development platform. The company was established by a team that included Ying Bo, who became its chairman and chief executive. From its early days, Abogen focused on the two core challenges of mRNA medicine: designing stable and effective mRNA sequences, and delivering them safely into cells. It developed a proprietary lipid nanoparticle (LNP) delivery system as the foundation of its platform. The company's profile rose significantly during the COVID-19 pandemic. Abogen partnered with the Academy of Military Medical Sciences and Walvax Biotechnology to develop ARCoV, an mRNA vaccine candidate against SARS-CoV-2. ARCoV advanced into clinical trials, making Abogen one of the earliest Chinese companies to bring an mRNA COVID-19 vaccine candidate into human testing. The candidate was noted for being designed to remain stable at standard refrigerator temperatures, which was seen as an advantage for distribution in China and other markets with less developed cold-chain logistics. As interest in mRNA technology grew globally, Abogen attracted substantial investment from venture capital and strategic investors. The company expanded its research and development activities and invested in manufacturing capacity in China, aiming to support both its COVID-19 program and a broader pipeline. Beyond COVID-19, Abogen has worked on mRNA vaccine candidates for other infectious diseases and on mRNA-based therapeutics, including in oncology. Abogen remains a private company and does not publicly report detailed financial results. Its history reflects the broader emergence of China's mRNA sector, in which domestic firms have sought to build capabilities across the full value chain, from sequence design and delivery to clinical development and manufacturing.

• 2021

  ARCoV advanced into clinical trials, making Abogen one of the earliest Chinese firms to test an mRNA COVID-19 vaccine in humans.

• 2020

  Partnered with the Academy of Military Medical Sciences and Walvax Biotechnology to develop the ARCoV COVID-19 mRNA vaccine candidate.

• 2019

  Abogen Biosciences founded in Suzhou, China.

Chinese mRNA platform biotechnology company focused on vaccines and therapeutics.

• ARCoV

  COVID-19 mRNA vaccine candidate developed with the Academy of Military Medical Sciences and Walvax Biotechnology.

• 2026.10.02

  Reported2026.10.02

  Novartis signs licensing agreement with Abogen Biosciences worth up to $7.8 billion[2]诺华与艾博生物签署最高78亿美元的授权协议cnbc.com

  Swiss pharmaceutical company Novartis has entered a licensing agreement with China-based Abogen Biosciences worth up to $7.8 billion. Novartis will pay $575 million upfront for global rights to Abogen's lead asset, an early-stage experimental messenger RNA therapy for autoimmune disease, with an additional $7.2 billion in milestone payments, plus an exclusive option to license Abogen's assets developed on its RNA platform. Abogen announced the deal in a statement on Friday.

  Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.

• Unconfirmed

  Reported2021.08.19

  Abogen completes over $700 million Series C funding[3]艾博生物完成超7亿美元C轮融资finance.sina.com.cn

  Abogen announced that it had completed a Series C financing round totaling more than $700 million, led by Temasek, Invesco Developing Markets Fund, Zhengxingu Capital, Hillhouse Ventures, Yunfeng Capital and Lilly Asia Ventures, among others.

Read more

1. 1Google Newsnews.google.com
2. 2诺华与艾博生物签署最高78亿美元的授权协议cnbc.com
3. 3艾博生物完成超7亿美元C轮融资finance.sina.com.cn